EMA Authorised: Talvey (talquetamab) — Janssen-Cilag International N.V.

View source ↗

Summary

The European Medicines Agency authorised Talvey (talquetamab) for the treatment of multiple myeloma, with conditional approval and orphan medicine designation g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TALVEY (talquetamab)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Janssen-Cilag International N.V.. Decision date: 16/10/2025. Conditional approval. Orphan medicine